MIRMStock
Verdicts genuinely change. Free email alert the moment MIRM's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
MIRM is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 451 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-06-30. These ratios come from the issuer's own published statements rather than structured SEC data.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.65% | 30.00% | Pass |
| Interest-bearing investments | 6.69% | 30.00% | Pass |
| Non-permissible income | 2.44% | 5.00% | Pass |
Usmani Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 73.01% | 33.00% | Fail |
| Interest-bearing investments | 41.94% | 33.00% | Fail |
| Non-liquid assets | 44.15% | at least 20.00% | Pass |
| Non-permissible income | 2.44% | 5.00% | Pass |
MSCI Fail 1 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 73.01% | 33.33% | Fail |
| Cash + interest-bearing securities | 41.94% | 33.33% | Fail |
| Accounts receivable | 55.85% | 33.33% | Fail |
| Non-permissible income | 2.44% | 5.00% | Pass |
FTSE Fail 1 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 71.78% | 33.33% | Fail |
| Cash + interest-bearing securities | 41.94% | 33.33% | Fail |
| Accounts receivable | 55.85% | 50.00% | Fail |
| Non-permissible income | 2.44% | 5.00% | Pass |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 15.39% | 33.00% | Pass |
| Cash + interest-bearing securities | 8.84% | 33.00% | Pass |
| Accounts receivable | 2.93% | 33.00% | Pass |
| Non-permissible income | 2.44% | 5.00% | Pass |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 19.28% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.08% | 49.00% | Pass |
| Accounts receivable | 3.67% | 49.00% | Pass |
| Non-permissible income | 2.44% | 5.00% | Pass |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 19.28% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.08% | 33.33% | Pass |
| Accounts receivable | 14.75% | 49.00% | Pass |
| Non-permissible income | 2.44% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from MIRM's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $521.3M | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $750.1M | 2026-06-30 | ConvertibleLongTermNotesPayable |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $438.3M | 2026-06-30 | CashAndCashEquivalentsAtCarryingValue, ShortTermInvestments |
| Total assetsBalance sheet total | $1.0B | 2026-06-30 | Assets |
| Market capDenominator for AAOIFI | $6.6B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $3.0B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $3.8B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $12.7M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
What changed, and when
Verdict history for MIRM. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for MIRM has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
ℹ️ no compliance scan has run for 6 days - this is not a reading of today
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $10M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 60.90 | NEUTRAL |
| Stochastic %K (14) | 71.97 | NEUTRAL |
| CCI (20) | 184.97 | SELL |
| Williams %R (14) | -28.03 | NEUTRAL |
| MACD (12,26,9) | 1.70 | BUY |
| ROC (10) | 16.58 | BUY |
| Momentum (10) | 13.33 | BUY |
| EMA (10) | 89.32 | BUY |
| SMA (10) | 88.30 | BUY |
| EMA (20) | 87.47 | BUY |
| SMA (20) | 85.27 | BUY |
| EMA (30) | 87.68 | BUY |
| SMA (30) | 84.73 | BUY |
| EMA (50) | 89.78 | BUY |
| SMA (50) | 89.29 | BUY |
| EMA (100) | 93.56 | BUY |
| SMA (100) | 99.82 | SELL |
| EMA (200) | 92.57 | BUY |
| SMA (200) | 98.53 | SELL |
About MIRM
Healthcare · Biotechnology
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Background via Yahoo Finance — informational, not part of the verdict.
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 13.0%, RSI in healthy zone. High conviction entry. Use `!plan MIRM [entry] [stop] [target]` to size the position properly.
Scores: 4 bullish / 0 bearish
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 64 |
| ⏰ 4H | BULLISH | 36 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-03 · Asset managers net 928584 (+5135)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.